Eszter Dalma Palinkas

Dr. Eszter Dalma Palinkas

Doctoral School of Clinical Medicine, University of Szeged
+2
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EPEugenio Picano
Eugenio Picano
QCQuirino Ciampi
Quirino Ciampi
LCLauro Cortigiani
Lauro Cortigiani
AAAdelaide M. Arruda-Olson
Adelaide M. Arruda-Olson
Clarissa Borguezan DarosClarissa Borguezan Daros
Clarissa Borguezan Daros
T(The Stress Echo 2030 Study Group of the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI)
The Stress Echo 2030 Study Group of the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI)
With stress echo (SE) 2020 study, a new standard of practice in stress imaging was developed and disseminated: the ABCDE protocol for functional testing within and beyond CAD. ABCDE protocol was the fruit of SE 2020, and is the seed of SE 2030, which is articulated in 12 projects: 1-SE in coronary artery disease (SECAD); 2-SE in diastolic heart failure (SEDIA); 3-SE in hypertrophic cardiomyopathy (SEHCA); 4-SE post-chest radiotherapy and chemotherapy (SERA); 5-Artificial intelligence SE evaluation (AI-SEE); 6-Environmental stress echocardiography and air pollution (ESTER); 7-SE in repaired Tetralogy of Fallot (SETOF); 8-SE in post-COVID-19 (SECOV); 9: Recovery by stress echo of conventionally unfit donor good hearts (RESURGE); 10-SE for mitral ischemic regurgitation (SEMIR); 11-SE in valvular heart disease (SEVA); 12-SE for coronary vasospasm (SESPASM). The study aims to recruit in the next 5 years (2021–2025) ≥10,000 patients followed for ≥5 years (up to 2030) from ≥20 quality-controlled laboratories from ≥10 countries. In this COVID-19 era of sustainable health care delivery, SE2030 will provide the evidence to finally recommend SE as the optimal and versatile imaging modality for functional testing anywhere, any time, and in any patient.

24 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FGFrancesca Girolami
Francesca Girolami
AGAlessia Gozzini
Alessia Gozzini
Eszter Dalma PalinkasEszter Dalma Palinkas
Eszter Dalma Palinkas
ABAdelaide Ballerini
Adelaide Ballerini
ATAlessia Tomberli
Alessia Tomberli
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto
Genetic counselling and genetic testing in hypertrophic cardiomyopathy (HCM) represent an integral part of the diagnostic algorithm to confirm the diagnosis, distinguish it from phenocopies, and suggest tailored therapeutic intervention strategies. Additionally, they enable cascade genetic testing in the family. With the implementation of Next Generation Sequencing technologies (NGS), the interpretation of genetic data has become more complex. In this regard, cardiologists play a central role, aiding geneticists to correctly evaluate the pathogenicity of the identified genetic alterations. In the ideal setting, geneticists and cardiologists must work side by side to diagnose HCM as well as convey the correct information to patients in response to their many questions and concerns. After a brief overview of the role of genetics in the diagnosis of HCM, we present and discuss the frequently asked questions by HCM patients throughout our 20-year genetic counselling experience. Appropriate communication between the team and the families is key to the goal of delivering the full potential of genetic testing to our patients.

3 May 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Róbert SeppRóbert Sepp
Róbert Sepp
LHLidia Hategan
Lidia Hategan
BCBeáta Csányi
Beáta Csányi
JBJános Borbás
János Borbás
ATAnnamária Tringer
Annamária Tringer
INIstván Nagy
István Nagy
Hypertrophic cardiomyopathy (HCM) is a primary disease of the myocardium most commonly caused by mutations in sarcomeric genes. We aimed to perform a nationwide large-scale genetic analysis of a previously unreported, representative HCM cohort in Hungary. A total of 242 consecutive HCM index patients (127 men, 44 ± 11 years) were studied with next generation sequencing using a custom-designed gene-panel comprising 98 cardiomyopathy-related genes. A total of 90 patients (37%) carried pathogenic/likely pathogenic (P/LP) variants. The percentage of patients with P/LP variants in genes with definitive evidence for HCM association was 93%. Most of the patients with P/LP variants had mutations in MYBPC3 (55 pts, 61%) and in MYH7 (21 pts, 23%). Double P/LP variants were present in four patients (1.7%). P/LP variants in other genes could be detected in ≤3% of patients. Of the patients without P/LP variants, 46 patients (19%) carried a variant of unknown significance. Non-HCM P/LP variants were identified in six patients (2.5%), with two in RAF1 (p.Leu633Val, p.Ser257Leu) and one in DES (p.Arg406Trp), FHL1 (p.Glu96Ter), TTN (p.Lys23480fs), and in the mitochondrial genome (m.3243A>G). Frameshift, nonsense, and splice-variants made up 82% of all P/LP MYBPC3 variants. In all the other genes, missense mutations were the dominant form of variants. The MYBPC3 p.Gln1233Ter, the MYBPC3 p.Pro955ArgfsTer95, and the MYBPC3 p.Ser593ProfsTer11 variants were identified in 12, 7, and 13 patients, respectively. These three variants made up 36% of all patients with identified P/LP variants, raising the possibility of a possible founder effect for these mutations. Similar to other HCM populations, the MYBPC3 and the MYH7 genes seemed to be the most frequently affected genes in Hungarian HCM patients. The high prevalence of three MYBPC3 mutations raises the possibility of a founder effect in our HCM cohort.

24 March 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
QCQuirino Ciampi
Quirino Ciampi
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto
JPJesus Peteiro
Jesus Peteiro
MDMaria Grazia D’alfonso
Maria Grazia D’alfonso
FMFabio Mori
Fabio Mori
T(the Stress Echo 2020 Study Group on behalf of the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI)
the Stress Echo 2020 Study Group on behalf of the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI)
Background: Sympathetic dysfunction can be evaluated by heart rate reserve (HRR) with exercise test. Objectives: To determine the value of HRR in predicting outcome of patients with hypertrophic cardiomyopathy (HCM). Methods: We enrolled 917 HCM patients (age = 49 ± 15 years, 516 men) assessed with exercise stress echocardiography (ESE) in 11 centres. ESE modality was semi-supine bicycle in 51 patients (6%), upright bicycle in 476 (52%), and treadmill in 390 (42%). During ESE, we assessed left ventricular outflow tract obstruction (LVOTO), stress-induced new regional wall motion abnormalities (RWMA), and HRR (peak/rest heart rate, HR). By selection, all patients completed the follow-up. Mortality was the predetermined outcome measure Results: During ESE, RWMA occurred in 22 patients (2.4%) and LVOTO (≥50 mmHg) in 281 (30.4%). HRR was 1.90 ± 0.40 (lowest quartile ≤ 1.61, highest quartile > 2.13). Higher resting heart rate (odds ratio 1.027, 95% CI: 1.018–1.036, p < 0.001), older age (odds ratio 1.021, 95% CI: 1.009–1.033, p < 0.001), lower exercise tolerance (mets, odds ratio 0.761, 95% CI: 0.708–0.817, p < 0.001) and resting LVOTO (odds ratio 1.504, 95% CI: 1.043–2.170, p = 0.029) predicted a reduced HRR. During a median follow-up of 89 months (interquartile range: 36–145 months), 90 all-cause deaths occurred. At multivariable analysis, lowest quartile HRR (Hazard ratio 2.354, 95% CI 1.116–4.968 p = 0.025) and RWMA (Hazard ratio 3.279, 95% CI 1.441–7.461 p = 0.004) independently predicted death, in addition to age (Hazard ratio 1.064, 95% CI 1.043–1.085 p < 0.001) and maximal wall thickness (Hazard ratio 1.081, 95% CI 1.037–1.128, p < 0.001). Conclusions: A blunted HRR during ESE predicts survival independently of RWMA in HCM patients.

14 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Carlos CotrimCarlos Cotrim
Carlos Cotrim
Eszter Dalma PalinkasEszter Dalma Palinkas
Eszter Dalma Palinkas
NCNuno Alexandre Simões Cotrim
Nuno Alexandre Simões Cotrim
This review aims to serve as a guide for clinical practice and to appraise the current knowledge on exercise stress echocardiography in the evaluation of intraventricular obstruction in HCM, in patients with cardiac syndrome X, in athletes with symptoms related to exercise, and in patients with normal left ventricular systolic function and exercise-related unexplained tiredness. The appearance of intraventricular obstruction while exercising is considered rare, and it usually occurs in patients with hypertrophy of the left ventricle. The occurrence of intraventricular obstruction when exercising has been evidenced in patients with hypertrophic cardiomyopathy, athletes, patients with cardiac syndrome X, patients with syncope or dizziness related to exercise, and patients with dyspnea and preserved ejection fraction. The clinical significance of this observation and the exercise modality that is most likely to trigger intraventricular obstruction remains unknown. Supine exercise and lying supine after exercise are less technically demanding, but they are also less physiologically demanding than upright exercise. Importantly, in everyday life, human beings generally do not become supine after exercise, as takes place in post-exercise treadmill stress echocardiograms in most echocardiography labs. The presence of induced intraventricular obstruction might be considered when patients have exercise-related symptoms that are not understood, and to assess prognosis in hypertrophic cardiomyopathy.

1 March 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
AFAnnamaria Del Franco
Annamaria Del Franco
Eszter Dalma PalinkasEszter Dalma Palinkas
Eszter Dalma Palinkas
Clarissa Carmona de Azevedo BellagambaClarissa Carmona de Azevedo Bellagamba
Clarissa Carmona de Azevedo Bellagamba
GBGiulia Biagioni
Giulia Biagioni
MZmattia zampieri
mattia zampieri
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto